Hanmi Pharmaceutical’s eldest son, Im Jong-yoon: “We need to hold an interim shareholders’ meeting… we need to change the directors.”

“Will hold an interim shareholders’ meeting to attempt board member replacement”
“Will request investigation by a third party for unfair trade practices”,

[Seoul=Newsis] Hanmi Pharmaceutical’s internal director Lim Jong-yoon met with reporters on the 2nd. 2024.09.02. [email protected] *Prohibition of reproduction and DB usage,
,
, ‘[Seoul=Newsis] Reporter Song Yeon-joo = Lim Jong-yoon, the son of the founding family who failed in his attempt to become the CEO of Hanmi Pharmaceutical, stated that he will attempt to replace the board members through an interim shareholders’ meeting.’,
,
, ‘Lim Jong-yoon met with reporters after a Hanmi Pharmaceutical board meeting held in Bangi-dong, Seoul on the 2nd, saying, “I tried to enter the company as the CEO to address internal issues of Hanmi Pharmaceutical, but it didn’t work out,” and “The previously appointed directors opposing the new management team officially.” ‘,
,
, ‘He further stated, “We will consider removing the current board members through the convening of an interim shareholders’ meeting.”‘,
,
, ‘He also claimed the possibility of foul play in the board meeting process. Lim said, “I expected us to have an advantage with a 6 to 4 ratio, but the opinions of two people changed, and I see that there was foul play in the process,” and “If there was any foul play, we will respond actively.”‘,
,
, ‘Previously, Lim, who is the largest shareholder in the bio company DX & VX, mentioned the need to request an investigation by a third party regarding allegations such as the suspected preferential treatment towards Lim’s owned Hong Kong Kory Group and the recent controversy. DX & VX has maintained a close cooperative relationship with the Kory Group.’,
,
, ‘He said, “For unfair proceedings or issues, we will petition the audit committee or an external third party,” and “We are also considering halting transactions between the Kory Group and Beijing Hanmi.”‘,
,
, ‘Lim expressed concerns that the internal conflict within the Hanmi Group may lead to potential shareholders’ meetings for Hanmi Pharmaceutical and Hanmi Science. He stated, “How much of a waste of time is it to not discuss new drugs and just waste this time,” and “As the family side cannot control through shares, they will continue to add new board members, so the management dispute is expected to continue until new members are added.”‘,
,
, ‘Meanwhile, at the Hanmi Pharmaceutical board meeting held in the morning on that day, Lim Jong-yoon’s proposal for the appointment of a sole CEO was discussed but not approved. As the appointment of the new CEO was rejected, the current CEO, Park Jae-hyun’s position remains unchanged.’,
,
, ‘Also, the issue of changing the CEO of Beijing Hanmi Pharmaceutical and appointing a new CEO were both rejected.’,
,